Raulee Morello, MD
Surgical Oncology · Bedford, TXNPI 1073961751
Payments from drug & device makers
Across 34 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elucent Medical$195
- Takeda Pharmaceuticals U.S.A., Inc.$80
- Incyte Corporation$72
- AstraZeneca$64
- Johnson & Johnson$63
- Merck$58
- plus $389 from 15 others
What the payments were for
- Food & beverage$922100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elucent Medical | 2 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Incyte Corporation | 3 | $72 |
| AstraZeneca | 3 | $64 |
| Johnson & Johnson(2 entities) | 3 | $63 |
| Merck | 2 | $58 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Sobi, Inc | 2 | $42 |
| Pharmacosmos Therapeutics Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Foundation Medicine, Inc. | 1 | $26 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Sanofi | 1 | $25 |
| Cardinal Health 414 LLC | 1 | $23 |
| Fennec Pharmaceuticals, Inc. | 1 | $21 |
| Iovance Biotherapeutics, Inc. | 1 | $21 |
| Merit Medical Systems Inc | 1 | $20 |
| Novartis | 1 | $20 |
| Medtronic | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
How this compares
$922 in reported general payments places this provider in the 35th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $58 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Bedford
- Jennifer WargoHouston$6M
- Ernest CampHouston$3.6M
- Hop Tran CaoHouston$928K
- Elizabeth GrubbsHouston$750K
- Alastair ThompsonHouston$568K
- Merrick RossHouston$283K
- Adam YoppDallas$281K
- Allison DipasqualeDallas$272K
- Patricio PolancoDallas$219K
- Steven CurleyTyler$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.